On Nov. 16, 2023, the CDC announced the release of more than 77,000 additional doses of Beyfortusﾙ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.

The CDC and FDA continued to be in close contact with manufacturers to ensure the availability of additional doses through end of this year and for early 2024 to meet the demand.